Posttransplant lymphoproliferative disorder is one of the most important complications of solid-organ transplant in terms of malignancy. Here, we report a case of Epstein-Barr-virus-negative posttransplant lymphoproliferative disorder of the T-cell type, involving the lung, in a renal transplant recipient. A 23-year-old woman received a living-related renal transplant in 2002. She presented with a 6-month history of weight loss, malaise, night sweats, and lymphadenopathy 6 years after the transplant. Chest radiograph showed miliary opacities. We performed a biopsy of the submandibular mass and computed-tomography-guided transthoracic needle biopsy of the lung. Pathological investigation of lymphadenopathy and lung were inconsistent with posttransplant lymphoproliferative disorder of T-cell type. After the diagnosis of posttransplant lymphoproliferative disorder, her immunosuppressive regimen was modified, and she was treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, ifosfamide, carboplatin, and etoposide chemotherapies, which resulted in partial remission. Posttransplant lymphoproliferative disorders may be seen as an atypical presentation; the differential diagnosis should be thought of pulmonary infiltrates in renal transplant recipients.
Download full-text PDF |
Source |
---|
Ann Intern Med
January 2025
Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (M.C.-P., R.B.M., C.M.P.).
Background: Prior studies indicate that 1% to 4% of Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+/R-) kidneys develop posttransplant lymphoproliferative disorder (PTLD). However, these estimates are based on limited data that lack granularity.
Objective: To determine the associations between pretransplant EBV D+/R- and recipient EBV-seropositive status (R+) and the outcomes of PTLD and graft and patient survival among adult kidney transplant recipients.
EJHaem
February 2025
Department of Lymphoma and Myeloma Research Center Beijing Gobroad Boren Hospital Beijing China.
Here, we report a case of Epstein-Barr virus-positive central nervous system-post-transplant lymphoproliferative disorder (CNS-PTLD) patient who failed to achieve complete metabolic remission (CMR) after successively trying a methotrexate-based regimen combined with orelabrutinib or whole-brain radiotherapy and encountered intracranial hemorrhage during orelabrutinib treatment. Ultimately, the patient achieved CMR after one cycle of acalabrutinib in combination with temozolomide, teniposide, liposomal doxorubicin, dexamethasone, and rituximab (TEDDi-R). Following another cycle of TEDDi-R treatment, he has been receiving acalabrutinib maintenance up to now and remained in CMR.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
January 2025
Department of Hematology, University of Occupational and Environmental Health, Kitakyushu, Japan. Electronic address:
Background: In vivo T-cell depletion with antithymocyte globulin (ATG), especially at high-doses has been shown to be associated with increased incidence of infections after allogeneic hematopoietic stem cell transplantation (HSCT). However, it remains unclear whether ATG, even at low-doses increases the risk of posttransplant infections in the high-risk HSCT setting.
Patients And Methods: We conducted a single-center retrospective study of viral and fungal infections early after transplantation, using the data from 82 patients with hematological malignancies.
Am J Case Rep
January 2025
Division of Transplant Surgery, Department of Surgery, University of Virginia School of Medicine, UVA Health, Charlottesville, VA, USA.
BACKGROUND Post-transplant lymphoproliferative disorder (PTLD) encompasses a group of disorders ranging from hyperplastic to malignant lymphoid proliferations in the post-transplant period owing to immunosuppression, often in the setting of EBV transformation. PTLD is a rare complication of immunosuppression that, like lymphomas, can have a variable presentation based on disease localization. We report a case of PTLD mass effect at the porta hepatis for the first time in the literature, resulting in hepatic artery stenosis (HAS) and common hepatic duct obstruction.
View Article and Find Full Text PDFQuant Imaging Med Surg
January 2025
Department of Ultrasound, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!